PL1919878T3 - Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy - Google Patents
Pochodne pirydazynonu jako agoniści receptora hormonu tarczycyInfo
- Publication number
- PL1919878T3 PL1919878T3 PL06792493T PL06792493T PL1919878T3 PL 1919878 T3 PL1919878 T3 PL 1919878T3 PL 06792493 T PL06792493 T PL 06792493T PL 06792493 T PL06792493 T PL 06792493T PL 1919878 T3 PL1919878 T3 PL 1919878T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor agonists
- hormone receptor
- thyroid hormone
- pyridazinone derivatives
- pyridazinone
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 229940127535 Thyroid Hormone Receptor Agonists Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70121505P | 2005-07-21 | 2005-07-21 | |
| EP06792493A EP1919878B1 (en) | 2005-07-21 | 2006-07-11 | Pyridazinone derivatives as thyroid hormone receptor agonists |
| PCT/EP2006/064093 WO2007009913A1 (en) | 2005-07-21 | 2006-07-11 | Pyridazinone derivatives as thyroid hormone receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1919878T3 true PL1919878T3 (pl) | 2011-03-31 |
Family
ID=37114368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06792493T PL1919878T3 (pl) | 2005-07-21 | 2006-07-11 | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7452882B2 (pl) |
| EP (1) | EP1919878B1 (pl) |
| JP (1) | JP5000649B2 (pl) |
| KR (1) | KR100965006B1 (pl) |
| CN (1) | CN101228135B (pl) |
| AR (1) | AR054848A1 (pl) |
| AT (1) | ATE480524T1 (pl) |
| AU (1) | AU2006271721C1 (pl) |
| BR (1) | BRPI0613754B8 (pl) |
| CA (1) | CA2614529C (pl) |
| CR (1) | CR9644A (pl) |
| CY (1) | CY1110929T1 (pl) |
| DE (1) | DE602006016821D1 (pl) |
| DK (1) | DK1919878T3 (pl) |
| EC (1) | ECSP088120A (pl) |
| ES (1) | ES2349131T3 (pl) |
| HR (1) | HRP20100633T1 (pl) |
| IL (1) | IL188476A (pl) |
| MA (1) | MA29731B1 (pl) |
| MX (1) | MX2008000818A (pl) |
| MY (1) | MY142861A (pl) |
| NO (1) | NO340679B1 (pl) |
| NZ (1) | NZ565190A (pl) |
| PL (1) | PL1919878T3 (pl) |
| PT (1) | PT1919878E (pl) |
| RS (1) | RS51639B (pl) |
| RU (1) | RU2379295C2 (pl) |
| TW (1) | TWI330636B (pl) |
| UA (1) | UA88104C2 (pl) |
| WO (1) | WO2007009913A1 (pl) |
| ZA (1) | ZA200800405B (pl) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| KR100965006B1 (ko) | 2005-07-21 | 2010-06-21 | 에프. 호프만-라 로슈 아게 | 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체 |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| JPWO2008133141A1 (ja) * | 2007-04-24 | 2010-07-22 | 東洋紡績株式会社 | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
| UA98962C2 (ru) * | 2007-06-06 | 2012-07-10 | Торрент Фармасьютикалз Лтд. | Аналоги тиреоидного гормона, фармацевтическая композиция, которая их содержит, способ лечения с их использованием, их применение и способ получения |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| US8268827B2 (en) | 2007-11-15 | 2012-09-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. | Pyridazinone derivatives as PARP inhibitors |
| KR100981781B1 (ko) | 2008-02-29 | 2010-09-10 | 재단법인 한국원자력의학원 | 방사선 치료용 콜리메이터 장치 및 그 장치를 이용한방사선 치료장치 |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102459185B (zh) | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| JP5847533B2 (ja) * | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| SG10201705984XA (en) | 2012-09-17 | 2017-08-30 | Madrigal Pharmaceuticals Inc | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| CN105272927A (zh) * | 2015-11-17 | 2016-01-27 | 华中药业股份有限公司 | 一种制备氯氮卓的新方法 |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| JP2020500199A (ja) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | グリコーゲン蓄積症の治療方法 |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US12090252B2 (en) | 2017-09-14 | 2024-09-17 | Riken | Method for producing retinal tissues |
| CN111646979B (zh) * | 2018-01-23 | 2021-08-31 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| CN111954518B (zh) | 2018-04-16 | 2024-04-05 | 尤利亚·采蒂 | 包含甲状腺激素的用于吸入的医药干燥粉末组合物 |
| JP7181386B2 (ja) * | 2018-06-12 | 2022-11-30 | スーチョワン ハイスコ ファーマスーティカル カンパニー リミテッド | 甲状腺ホルモン受容体アゴニスト及びその用途 |
| US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
| TW202019914A (zh) * | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式 |
| EP3840755A4 (en) * | 2018-08-24 | 2022-04-20 | Terns, Inc. | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
| WO2020049556A1 (en) * | 2018-09-06 | 2020-03-12 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| TWI840423B (zh) | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN119552152A (zh) * | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111592528A (zh) * | 2019-02-20 | 2020-08-28 | 苏州泽璟生物制药股份有限公司 | 氘代的哒嗪酮及其衍生物和药物组合物 |
| EP3927693A4 (en) | 2019-02-21 | 2023-04-05 | Nanjing Ruijie Pharma Co., Ltd. | NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS |
| KR20210138639A (ko) | 2019-03-13 | 2021-11-19 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트 |
| SG11202111552YA (en) * | 2019-05-08 | 2021-11-29 | Aligos Therapeutics Inc | MODULATORS OF THR-ß AND METHODS OF USE THEREOF |
| TW202108556A (zh) * | 2019-05-10 | 2021-03-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種噠嗪酮衍生物及其應用 |
| WO2020239076A1 (zh) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| GB2603330B (en) | 2019-08-19 | 2023-08-09 | Hepagene Therapeutics Hk Ltd | Heterocyclic THR-B receptor agonist compound and preparation method and use therefor |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| EP4017875A4 (en) * | 2019-08-23 | 2023-05-03 | Terns Pharmaceuticals, Inc. | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
| WO2021043185A1 (en) * | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| CN114375193B (zh) * | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| JP7634526B2 (ja) * | 2019-09-24 | 2025-02-21 | ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 | 甲状腺ホルモンベータ受容体アゴニストとしての化合物及びその使用 |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| EP4083024A4 (en) * | 2019-11-26 | 2023-11-01 | KPC Pharmaceuticals, Inc. | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF |
| CN114787153A (zh) | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN113045551B (zh) * | 2019-12-27 | 2024-07-09 | 广东东阳光药业股份有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| JP7728265B2 (ja) | 2020-01-13 | 2025-08-22 | エコジーン インコーポレイテッド | 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン |
| CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
| CN113698388B (zh) * | 2020-05-20 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| EP4159723B1 (en) | 2020-06-02 | 2025-07-23 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Novel thyroid hormone beta receptor agonist |
| CN116056709A (zh) * | 2020-08-27 | 2023-05-02 | 益方生物科技(上海)股份有限公司 | 哒嗪酮化合物 |
| AU2021341182A1 (en) * | 2020-09-10 | 2023-04-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of resmetirom, preparation method therefor, and use thereof |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| EP4201428A4 (en) | 2020-09-11 | 2024-09-11 | Sumitomo Pharma Co., Ltd. | MEDIUM FOR TISSUE INTENDED FOR TRANSPLANTATION |
| CA3194226A1 (en) | 2020-09-11 | 2022-03-17 | Riken | Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same |
| WO2022068915A1 (zh) * | 2020-09-30 | 2022-04-07 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用 |
| US20230364099A1 (en) | 2020-10-19 | 2023-11-16 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| TW202233583A (zh) * | 2020-10-23 | 2022-09-01 | 美商瑪德瑞高製藥公司 | 製備嗒酮衍生物之方法 |
| CN114437042A (zh) * | 2020-11-03 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 酞嗪类化合物的晶型及其制备方法 |
| EP4240737A2 (en) * | 2020-11-06 | 2023-09-13 | Aligos Therapeutics, Inc. | Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists |
| CN112645936B (zh) | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
| CN114685450A (zh) * | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| CN116063296B (zh) * | 2021-11-02 | 2025-08-19 | 凯思凯迪（上海）医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| US20250019652A1 (en) | 2021-11-19 | 2025-01-16 | Riken | Production method for sheet-like retinal tissue |
| CN116836158A (zh) * | 2022-03-23 | 2023-10-03 | 凯思凯迪（上海）医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| WO2024084491A1 (en) * | 2022-10-21 | 2024-04-25 | Mehta Nilesh Vipinchandra | Process for synthesis of res metirom and its intermediates thereof |
| CN118146217A (zh) | 2022-12-07 | 2024-06-07 | 昆药集团股份有限公司 | 一种甲状腺激素β受体激动剂、晶型、制备方法和用途 |
| CN115650928B (zh) * | 2022-12-28 | 2023-03-31 | 凯思凯旭(上海)医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
| WO2024141076A1 (en) * | 2022-12-29 | 2024-07-04 | Gannex Pharma Co., Ltd. | Prodrugs to thyroid hormone analogs and method of making and use thereof |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| CN116768802B (zh) * | 2023-05-25 | 2025-11-21 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗的合成方法 |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN117263870A (zh) * | 2023-09-21 | 2023-12-22 | 江西同和药业股份有限公司 | 一种Resmetirom关键中间体III的制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025191457A1 (en) * | 2024-03-13 | 2025-09-18 | Morepen Laboratories Limited | Process for the preparation of pyridazinone derivative |
| WO2025230749A1 (en) | 2024-05-03 | 2025-11-06 | Aligos Therapeutics, Inc. | Methods of preparing 6-amino-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo-1 h-pyridazin-3-yl)oxy]phenyl]-4h- 1, 2, 4-tri-azine-3, 5-dione |
| CN119798230B (zh) * | 2025-03-13 | 2025-06-27 | 中国药科大学 | 吲哚酮类化合物及其在治疗急慢性肝病与促进组织修复中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582842A (en) * | 1981-02-25 | 1986-04-15 | Merck & Co., Inc. | Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor |
| GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| EP0728482A3 (en) | 1995-02-10 | 1999-10-20 | Smithkline Beecham Corporation | Use of hcp specific compounds to enhance erythropoiesis |
| FI974435A7 (fi) | 1995-06-06 | 1997-12-05 | Pfizer | Menetelmä 2,4-diklooripyridiinien muuttamiseksi 2-aryylioksi-4-kloorip yridiineiksi |
| WO1997002023A1 (en) | 1995-06-30 | 1997-01-23 | Smithkline Beecham Corporation | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| NZ504045A (en) * | 1997-11-19 | 2001-06-29 | Kowa Co | Pyridazine derivatives with inhibitory action against interleukin-1-beta production |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| CZ20013117A3 (cs) * | 1999-03-01 | 2002-06-12 | Pfizer Products Inc. | Oxamové kyseliny a jejich deriváty jako ligandy thyreoidního receptoru |
| CA2433100A1 (en) * | 2000-12-27 | 2002-07-04 | Helmut Haning | Indole derivatives as ligands of thyroid receptors |
| IL157031A0 (en) * | 2001-02-08 | 2004-02-08 | Karobio Ab | Thyroid receptor ligands |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| CA2518823A1 (en) * | 2003-03-24 | 2004-10-07 | F.Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| CA2559552A1 (en) * | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors |
| KR100965006B1 (ko) | 2005-07-21 | 2010-06-21 | 에프. 호프만-라 로슈 아게 | 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체 |
-
2006
- 2006-07-11 KR KR1020087001480A patent/KR100965006B1/ko active Active
- 2006-07-11 HR HR20100633T patent/HRP20100633T1/hr unknown
- 2006-07-11 NZ NZ565190A patent/NZ565190A/en unknown
- 2006-07-11 AT AT06792493T patent/ATE480524T1/de active
- 2006-07-11 JP JP2008521935A patent/JP5000649B2/ja active Active
- 2006-07-11 MX MX2008000818A patent/MX2008000818A/es active IP Right Grant
- 2006-07-11 DK DK06792493.6T patent/DK1919878T3/da active
- 2006-07-11 CA CA2614529A patent/CA2614529C/en active Active
- 2006-07-11 DE DE602006016821T patent/DE602006016821D1/de active Active
- 2006-07-11 PL PL06792493T patent/PL1919878T3/pl unknown
- 2006-07-11 RU RU2008106058/04A patent/RU2379295C2/ru active
- 2006-07-11 PT PT06792493T patent/PT1919878E/pt unknown
- 2006-07-11 CN CN2006800267317A patent/CN101228135B/zh active Active
- 2006-07-11 WO PCT/EP2006/064093 patent/WO2007009913A1/en not_active Ceased
- 2006-07-11 EP EP06792493A patent/EP1919878B1/en active Active
- 2006-07-11 BR BRPI0613754A patent/BRPI0613754B8/pt active IP Right Grant
- 2006-07-11 AU AU2006271721A patent/AU2006271721C1/en active Active
- 2006-07-11 RS RS20100527A patent/RS51639B/sr unknown
- 2006-07-11 ES ES06792493T patent/ES2349131T3/es active Active
- 2006-07-18 TW TW095126242A patent/TWI330636B/zh active
- 2006-07-18 US US11/488,870 patent/US7452882B2/en active Active
- 2006-07-19 AR ARP060103084A patent/AR054848A1/es active IP Right Grant
- 2006-07-19 MY MYPI20063456A patent/MY142861A/en unknown
- 2006-11-07 UA UAA200801933A patent/UA88104C2/ru unknown
-
2007
- 2007-12-27 IL IL188476A patent/IL188476A/en active IP Right Grant
-
2008
- 2008-01-04 NO NO20080058A patent/NO340679B1/no unknown
- 2008-01-08 CR CR9644A patent/CR9644A/es unknown
- 2008-01-14 ZA ZA2008/00405A patent/ZA200800405B/en unknown
- 2008-01-18 EC EC2008008120A patent/ECSP088120A/es unknown
- 2008-02-01 MA MA30618A patent/MA29731B1/fr unknown
- 2008-08-20 US US12/194,643 patent/US7807674B2/en active Active
-
2010
- 2010-11-22 CY CY20101101049T patent/CY1110929T1/el unknown
-
2015
- 2015-07-01 US US14/788,921 patent/USRE46024E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188476A0 (en) | Pyridazinone derivatives as thyroid hormone receptor agonists | |
| IL188550A0 (en) | Heterocyclic compounds as agonists for the thyroid receptor | |
| IL186150A0 (en) | Novel thiophene derivatives as sphingosine-1-1phosphate-1 receptor agonists | |
| IL178086A0 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| ZA200709086B (en) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
| ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
| IL194398A0 (en) | Bisadenosine compounds as adenosine a2a receptor agonists | |
| IL177059A0 (en) | Indazole-carboxamide compounds as 5-ht4 receptor agonists | |
| IL219590A0 (en) | Nuclear receptor binding agents | |
| EP2061470A4 (en) | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | |
| IL186883A0 (en) | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | |
| ZA200707142B (en) | Quinolinone compounds as 5-HT4 receptor agonists | |
| ZA200705103B (en) | Novel uses for estrogen beta agonists | |
| EP1849481A4 (en) | COMPOSITION FOR TOPICAL APPLICATION | |
| IL190119A0 (en) | Amino-alkyl-amide derivatives as ccr3 receptor ligands | |
| IL190093A0 (en) | Amino-alkyl-amide derivatives as ccr3 receptor ligands | |
| SI1919878T1 (sl) | Derivati piridazinona kot agonisti receptorja ĺ äśitniäśnega hormona | |
| GB0525029D0 (en) | Receptor Antagonist | |
| GB0516439D0 (en) | EP2 receptor agonists | |
| GB0516946D0 (en) | Receptor | |
| ZA200709829B (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| GB0408453D0 (en) | Leptin receptor agonists | |
| IL177721A0 (en) | Adenosine receptor agonists | |
| GB0522484D0 (en) | Receptor | |
| GB0522394D0 (en) | Receptor |